medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2018, Number 1

<< Back Next >>

Rev Mex Urol 2018; 78 (1)

Impact of type 2 diabetes mellitus on the TNM classification of kidney cancer

Uscanga-Yépez J, González-Oyervides R, Olvera-Posada D, Góngora-Cortéz J, Barrera-Juárez E

Language: Spanish
References: 30
Page: 1-8
PDF size: 308.51 Kb.


ABSTRACT

Objective: To evaluate the influence of type 2 diabetes mellitus on the TNM staging classification in patients with renal cell carcinoma treated through nephrectomy
Materials and Methods:2 test. Overall survival and recurrence-free survival were evaluated through the Kaplan-Meier test.
Results: A total of 18.6% of the 43 study patients presented with type 2 diabetes mellitus. T1b tumors predominated in 32.6% of the cases. No statistically significant differences were found in the comparison of pathologic tumor stage (p = 0.5), lymph node disease (p = 0.7), or metastasis (p = 0.5) between patients with and without diabetes. Median follow-up was 45 months and no differences were found in the comparison of overall survival and recurrence-free survival in the patients with type 2 diabetes mellitus (p = 0.76) and those without the pathology (p = 0.78).
Conclusions: Type 2 diabetes mellitus had no significant impact on the pathologic stage of renal cell carcinoma or on overall survival and recurrence-free survival in those patients.


REFERENCES

  1. Scosyrev E, Messing J, Noyes K, Veazie P, Messing, E. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: An overview. Urol Oncol Semin Orig Investig 2012;30:126-132.

  2. Cancer Facts and Figures 2014. [En línea]. Dirección URL: www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/.

  3. SINAIS/SINAVE/DGE/SALUD/Perfil epidemiológico de los tumores malignos en México. [En línea]. Dirección URL: http://www.epidemiologia.salud.gob.mx/doctos/infoepid/ publicaciones/2011/monografias/P_EPI_DE_LOS_TUMORES_ MALIGNOS_México.pdf. (2016)

  4. Navai N, Wood CG. Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol Semin Orig Investig 2012;30:220-224.

  5. Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: Perspectives of primary prevention. World J Urol 2010;28:247-252.

  6. Sun LM, et al. Hypertension and subsequent genitourinary and gynecologic cancers risk: a population-based cohort study. Medicine (Baltimore) 2015;94(16):e753.

  7. Chow WH, Gridley G, Fraumeni JF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343(18):1305-1311.

  8. Zelenko Z, Gallagher EJ. Diabetes and cancer. Endocrinol Metab Clin North Am 2014;43(1):167-185.

  9. Chen L, Li H, Gu L, Ma X, et al. The impact of diabetes mellitus on renal cell carcinoma prognosis. Medicine (Baltimore) 2015;94(11):1-8.

  10. Choi Y, Park B, Seo BC, Jeon SS, et al. Body mass index and survival in patients with renal cell carcinoma: A clinical-based cohort and meta-analysis. Int J Cancer 2012;132(3):625-34.

  11. Park YH, Lee JK, Kim KM, Kook HR, et al. Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma. J Urol 2014;192(4):1043-9.

  12. Choi, S, Min GE, Jeon SH, Lee HL, et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol 2013;1(2):365-368.

  13. Tseng C. Type 2 Diabetes Mellitus and Kidney Cancer Risk : A Retrospective Cohort Analysis of the National Health Insurance. PLoS One 2015;10(11):e0142480.

  14. Psutka SP, Stewart SB, Boorjian SA, Lohse CM, et al. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J Urol 2014;192(6):1620-1627.

  15. Lee S, Hong SK, Kwak C, Kim HH, et al. Prognostic significance of diabetes mellitus in localized renal cell carcinoma. Jpn J Clin Oncol 2012;42(4):318-324.

  16. Hofner T, Zeier M, Hatiboglu G, Eisen C, et al. The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J Urol 2014;32(6):1537-1542.

  17. Levey AS, Coresh J, Greene T, Stevens LA, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145(4):247-54.

  18. Barone BB, Yeh HC, Snyder CF, Peairs KS, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. JAMA 2008;300(23):2754-2764.

  19. Fukushima H, Masuda H, Yokoyama M, Tatokoro M, et al. Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol 2013;43(7):740-746.

  20. Ha YS, Kim WT, Yun SJ, Lee SC, et al. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann Surg Oncol 2013;20(11):3662-3668.

  21. Antonelli A, Arrighi N, Corti S, Zanotelli A, et al. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: A single-center retrospective study. Urol Oncol 2012;31(7):1310-1315.

  22. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132(6):2208-2225.

  23. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17(8):328-336.

  24. Rosendahl A, Forsberg G. Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int J Oncol 2004;25(5):1327-1336.

  25. Rosendahl AH, Holly JM, Celander M, Forsberg G. Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. Int J Cancer 2008;123(6):1286-91.

  26. Habib SL, Liang S. Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes. Oncotarget 2014;5(9):2542-2550.

  27. Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer : a meta-analysis of cohort studies. Diabetologia 2001;54(5):1013-1018.

  28. Denton MD, MAgee CC, Ovuworie C, Mauiyyedi S, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002;61(6):2201-2209.

  29. Seo MH, Lee WJ, Park CY, Kim SR, et al. Management of blood pressure in patients with type 2 diabetes mellitus: a nationwide survey in Korean. Diabetes Metab J 2011;35(4):348-353.

  30. Encuesta Nacional en Salud y Nutrición 2012. Instituto Nacional de Salud Pública en México. [En línea]. Dirección URL: .




2020     |     www.medigraphic.com